Related Experiment Videos
[Isosorbide 5-mononitrate (delayed release) in stable effort angina]
L Almenar Bonet1, V Miró Palau, J V Gimeno Gascón
1Servicio de Cardiología, Hospital La Fe, Valencia.
Revista Espanola De Cardiologia
|August 1, 1992
Summary
Sustained-release Isosorbide-5-Mononitrate (50 mg) effectively improved exercise tolerance and delayed angina onset in stable effort angina patients over 100 days. This treatment demonstrated significant benefits compared to placebo.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Stable effort angina significantly impacts patients' quality of life.
- Current treatments aim to improve exercise tolerance and reduce angina episodes.
Purpose of the Study:
- To evaluate the efficacy, tolerance, and hemodynamic effects of sustained-release Isosorbide-5-Mononitrate (50 mg) once daily.
- To assess the drug's impact on exercise capacity and angina onset in patients with stable effort angina.
Main Methods:
- A double-blind, randomized, crossover, placebo-controlled study.
- Inclusion of 10 patients with stable effort angina confirmed by positive exercise tests.
- Cycloergometry performed at baseline and at 4, 12, and 24 hours post-dose on days 1, 25, and 100.
Main Results:
- Significant increase in time to 1 mm ST-segment depression at 4 and 12 hours post-dose (p < 0.05).
- Considerable lengthening of time to angina onset at 4 and 12 hours post-dose (p < 0.05).
- Significantly greater exercise duration at 4 and 12 hours post-dose compared to placebo (p < 0.05).
Conclusions:
- Sustained-release Isosorbide-5-Mononitrate (50 mg) is effective in improving exercise tolerance and delaying angina in stable effort angina.
- The observed benefits were consistent over 100 days of treatment.
- The drug demonstrated good tolerance and favorable hemodynamic repercussions.